Takeda: Cytomegalovirus Infections trials
The registry lists 10 Cytomegalovirus Infections studies with Takeda as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 1Phase 2 2Phase 3 5No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) InfectionCompletedNCT05137717Phase 3Results posted
- Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or CidofovirCompletedNCT02931539Phase 3Results posted
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsCompletedNCT02927067Phase 3Results posted
- Study of SHP620 (Maribavir) in Healthy AdultsCompletedNCT02775240Phase 1Results posted
- Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant RecipientsCompletedNCT01611974Phase 2Results posted
- Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant RecipientsCompletedNCT00497796Phase 3Results posted
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant RecipientsCompletedNCT00411645Phase 3Results posted
- A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and CanadaCompletedNCT05576805
- A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and CanadaCompletedNCT05571137
- Maribavir for Prevention of CMV After Stem Cell TransplantsCompletedNCT00223925Phase 2